Avacopan as First-Line Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Steroid-Sparing Option

Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis

“…4 In between the completion of the ADVOCATE study (2019) and the approval of regulatory agencies, 30 patients with a high unmet medical need have been treated with avacopan through the Early Access Program (EAP). 5 , 6 Eligible for the EAP were patients with new or relapsing life- or organ-threatening ANCA-associated vasculitis, requiring an induction treatment, who also had a high risk of steroid-related complications. 5 …”

Cutaneous manifestations of microscopic polyangiitis successfully controlled with avacopan alone

“…4 In a study of nine AAV patients treated with avacopan plus rituximab or obinutuzumab as a steroid-sparing option, eight of the patients (89%) were in remission by month 12. 5 The efficacy of avacopan monotherapy for the cutaneous manifestations of MPA has not been previously reported, as far as we know. Notably, the edema and purpura resolved quickly after the start of avacopan in our case.…”

Avacopan as an additional therapeutic intervention to promote renal recovery in severe ANCA‐associated vasculitis: A case report

“…However, the ADVOCATE trial excluded patients with eGFR ≤15 mL/min/1.73 m 2 , 7 and consequently information is limited regarding the use of avacopan in these patients. Case series have demonstrated steroid‐sparing qualities when used either at induction, 9 or in patients with established difficult‐to‐treat AAV for the indications of steroid‐resistance, steroid‐dependence, or steroid‐related toxicity 10 . Furthermore, a recent case report discussed the use of avacopan at induction in combination with standard therapies in three patients initially requiring KRT, with the suggestion it may provide an incremental benefit 11…”